Fiji vs Saint Kitts and Nevis: Hepatitis B surface antigen (HBsAg) prevalence
Fiji
0.2%
in 2024
Saint Kitts and Nevis
0.2%
in 2024
Fiji rank
82nd
Saint Kitts and Nevis rank
82nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Fiji
- Saint Kitts and Nevis
How they compare
Fiji currently reports 0.2% against 0.2% in Saint Kitts and Nevis, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Saint Kitts and Nevis ahead.
Fiji ranks 82nd and Saint Kitts and Nevis ranks 82nd of 194 countries.
Across the 2 decades both report, Fiji averaged higher in 1 and Saint Kitts and Nevis in 1.
Head to head by decade
| Decade | Fiji | Saint Kitts and Nevis | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | Saint Kitts and Nevis |
| 2020s | 0.3% | 0.2% | 0.1% | Fiji |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Fiji or Saint Kitts and Nevis?
- Fiji, at 0.2% against 0.2% in Saint Kitts and Nevis as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Fiji and Saint Kitts and Nevis?
- 0.0%, with Fiji ahead.
- How many years of comparable data are there for Fiji and Saint Kitts and Nevis?
- 10 years are reported by both, from 2015 to 2024.
- How do Fiji and Saint Kitts and Nevis rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Fiji ranks 82nd and Saint Kitts and Nevis ranks 82nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.